Patents by Inventor Ben Whittaker

Ben Whittaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HPK1 antagonists and uses thereof
    Patent number: 12215105
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: February 4, 2025
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance, Robert Griffiths
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20250011331
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: August 3, 2022
    Publication date: January 9, 2025
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Daniel L. SEVERANCE, Steven K. ALBANESE
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20240025898
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: July 11, 2023
    Publication date: January 25, 2024
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition
    Patent number: 11649237
    Abstract: Provided herein, inter alia, are substituted imidazo[1,5-?]pyrazine compounds, compositions and methods for treating or preventing an IRE1?-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: May 16, 2023
    Assignees: Optikira LLC, The Regents of the University of California
    Inventors: Richard M. Keenan, Bradley J. Backes, Dustin J. Maly, Charles Reynolds, Ben Whittaker, Jamie Knight, Jonathan Mark Sutton, George Hynd, Feroz R. Papa, Scott A. Oakes
  • HPK1 antagonists and uses thereof
    Patent number: 11548890
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 10, 2023
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists
    Patent number: 11078201
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: August 3, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
    Patent number: 11034694
    Abstract: The present invention provides compounds of formula I: or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof. The present invention also provides methods for the inhibition of HPK1 and methods for the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 15, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists
    Patent number: 11028085
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 8, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
    Patent number: 11021481
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210087190
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 25, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER
  • SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210087189
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 25, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER
  • SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210078997
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210078998
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20210078996
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 18, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION
    Publication number: 20200354367
    Abstract: The present invention provides novel compounds, compositions and methods for treating or preventing an IRE1?-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.
    Type: Application
    Filed: August 31, 2018
    Publication date: November 12, 2020
    Inventors: Richard M. Keenan, Bradley J. Backes, Dustin J. Maly, Charles Reynolds, Ben Whittaker, Jamie Knight, Jon Sutton, George Hynd, Feroz R. Papa, Scott A. Oakes
  • 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors
    Patent number: 10087176
    Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: October 2, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Gabriele Amari, Elisabetta Armani, Mauro Riccaboni, Andrea Rizzi, Charles Baker-Glenn, Wesley Blackaby, Herve Van De Poel, Ben Whittaker
  • 3,5-DICHLORO,4-(3,4-(CYCLO-)ALKOXYPHENYL)--2-CARBONYLOXY)ETHYL)PYRIDINE DERIVATIVES AS PDE-4 INHIBITORS
    Publication number: 20170152256
    Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
    Type: Application
    Filed: June 4, 2014
    Publication date: June 1, 2017
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Gabriele AMARI, Elisabetta ARMANI, Mauro RICCABONI, Andrea RIZZI, Charles BAKER-GLENN, Wesley BLACKABY, Herve VAN DE POEL, Ben WHITTAKER
  • Fused triazole derivatives as gamma secretase modulators
    Patent number: 9527853
    Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: December 27, 2016
    Assignee: Ares Trading S.A.
    Inventors: Ben Whittaker, Chris Steele, David Hardick, Dale Mitchell, Vincent Pomel, Anna Quattropani, Dirk Beher
  • Compounds
    Patent number: 9199980
    Abstract: Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: December 1, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Elisabetta Armani, Gabriele Amari, Mauro Riccaboni, Andrea Rizzi, Charles Baker-Glenn, Wesley Blackaby, Herve′ Van de Poel, Ben Whittaker
  • Heteroaryl derivatives
    Patent number: 9133185
    Abstract: Compounds of formula (I) described herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: September 15, 2015
    Assignee: Chiesi Farmaceutici S.p.A
    Inventors: Gabriele Amari, Elisabetta Armani, Eleonora Ghidini, Charles Baker-Glenn, Hervé Van De Poël, Ben Whittaker